Lineage Cell Therapeutics, Inc.
AMEX:LCTXBiotechnology
Healthcare
$0.84 -2.80%
-$0.04 today
- Market cap
- $212.10M
- Beta
- 1.51
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
52W Low $0.85High $2.09
Volume 1.22M
Average 1.19M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$18.92M
FY 2025 · Annual
Investing Cash Flow
-$13.46M
FY 2025 · Annual
Financing Cash Flow
$26.95M
FY 2025 · Annual
-24.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.27M) | (26.35M) | (21.49M) | (18.61M) | (63.53M) |
| Depreciation & Amortization | 873K | 727K | 692K | 609K | 699K |
| Deferred Income Tax | (6M) | 0 | (1.8M) | 0 | (5.28M) |
| Stock-Based Compensation | 3.52M | 4.29M | 4.64M | 5.08M | 4.75M |
| Change in Working Capital | 21.11M | 18.67M | (10.8M) | (8.77M) | (4.11M) |
| Accounts Receivables | (857K) | 50.31M | (446K) | 106K | (316K) |
| Inventory | (72K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 21.65M | (18.7M) | (2.3M) | (1.68M) | 2.27M |
| Other Working Capital | 308K | (12.94M) | (8.06M) | (7.19M) | (6.07M) |
| Other Non-Cash Items | 202K | 3.73M | 195K | (1.4M) | 48.55M |
| Operating Cash Flow | (23.56M) | 1.06M | (28.57M) | (23.09M) | (18.92M) |
| Capital Expenditures | (354K) | (413K) | (674K) | (565K) | (522K) |
| Acquisitions (Net) | 10.09M | 45.75M | 0 | 0 | 0 |
| Purchases of Investments | 6.02M | (53.41M) | (16.4M) | (8.76M) | (14.94M) |
| Sales of Investments | (6.02M) | 7.67M | 63.53M | 7.02M | 2M |
| Other Investing Activities | 14K | (45.75M) | 0 | 0 | 0 |
| Investing Cash Flow | 9.75M | (46.16M) | 46.45M | (2.31M) | (13.46M) |
| Debt Repayment | (20K) | (32K) | (54K) | (54K) | (59K) |
| Common Stock Issued | 30.87M | 148K | 6.63M | 35.88M | 27.03M |
| Common Stock Repurchased | (54K) | (17K) | (37K) | (23K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.14M | 1.53M | (37K) | 58K | (16K) |
| Financing Cash Flow | 36.93M | 1.63M | 6.42M | 35.86M | 26.95M |
| Effect of Forex Changes | (20K) | (873K) | (250K) | (95K) | 396K |
| Net Change in Cash | 23.09M | (44.34M) | 24.06M | 10.36M | (5.03M) |
| Free Cash Flow | (23.92M) | 646K | (29.24M) | (23.66M) | (19.44M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$63.5M
+ D&A$699.0K
+ Stock-Based Comp$4.8M
- Deferred Tax-$5.3M
- Working Capital-$4.1M
+ Other Non-Cash$48.6M
= Operating Cash Flow-$18.9M
- Capex-$522.0K
= Free Cash Flow-$19.4M
Analysis
FY2025 free cash flow is -$19.4M. FCF conversion is 30.6% of net income. Operating cash flow was -$18.9M, with capex of -$522.0K. The largest bridge item is Other Non-Cash at $48.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 | |
| 8-K | Current report | Aug 6, 2026 | |
| SC 13G | SC 13G filing | Jul 29, 2026 |
Does LCTX generate free cash flow?
Lineage Cell Therapeutics, Inc. (LCTX) generated -$19.44M of free cash flow in fiscal 2025.
How much operating cash flow does LCTX produce?
Operating cash flow was -$18.92M, before capital expenditures of $522,000.00.
Continue the stock analysis
Jump to another research area for this company.